Litcius/Paper detail

Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Shuaixi Yang, Yuhang Wang, Jiachi Jia, Yingshuai Fang, Yabing Yang, Weitang Yuan, Junhong Hu

2024Cell Death and Disease52 citationsDOIOpen Access PDF

Abstract

Macrophages, as pivotal cells within the tumour microenvironment, significantly influence the impact of and reactions to treatments for solid tumours. The rapid evolution of bioengineering technology has revealed the vast potential of engineered macrophages in immunotherapy, disease diagnosis, and tissue engineering. Given this landscape, the goal of harnessing and innovating macrophages as a novel strategy for solid tumour immunotherapy cannot be overstated. The diverse strategies for engineered macrophages in the realm of cancer immunotherapy, encompassing macrophage drug delivery systems, chimeric antigen receptor macrophage therapy, and synergistic treatment approaches involving bacterial outer membrane vesicles and macrophages, are meticulously examined in this review. These methodologies are designed to enhance the therapeutic efficacy of macrophages against solid tumours, particularly those that are drug-resistant and metastatic. Collectively, these immunotherapies are poised to supplement and refine current solid tumour treatment paradigms, thus heralding a new frontier in the fight against malignant tumours.

Topics & Concepts

ImmunotherapyCancer immunotherapyMacrophageChimeric antigen receptorCancer researchTumor microenvironmentCancerDrug deliveryBiologyImmunologyMedicineImmune systemChemistryGeneticsOrganic chemistryBiochemistryIn vitroImmune cells in cancerNanoplatforms for cancer theranosticsPhagocytosis and Immune Regulation
Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy | Litcius